A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT)
and recommended Phase 2 dose (RP2D) in patients who receive FF-10832 (Gemcitabine Liposome
Injection) for treatment of advanced solid tumors.